Patient Leaflet Updated 22-Sep-2020 | Bayer plc
Magnevist 2mmol/l solution for injection
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes.
If you have any doubts or queries about your medication, please contact your doctor or pharmacist.
MAGNEVIST® 2 mmol/l solution for injection
dimeglumine gadopentetate
1. What Magnevist 2 mmol/l is and what it is used for
2. What you need to know before you are given Magnevist 2 mmol/l
3. How you will be given Magnevist 2 mmol/l
4. Possible side effects
5. How to store Magnevist 2 mmol/l
6. Contents of the pack and other information
Magnevist 2 mmol/l is used together with a technique called Magnetic Resonance Imaging (MRI) to create artificial contrast or enhancement to help make an MRI scan of your joints clearer.
MRI is a modern scanning technique which produces very high quality pictures of various parts of your body without using X-rays. The use of MRI can provide a quick, early and accurate diagnosis.
The scanner uses a strong magnetic field and radiowaves to measure the magnetic properties of body tissues. Using a computer, this information is converted into a black and white picture which can help your doctor see and investigate the differences between normal and abnormal tissue.
Sometimes MRI is used in areas where it cannot produce a clear black and white picture. This is when Magnevist 2 mmol/l is used. Magnevist 2 mmol/l produces a clearer image and allows the doctor to see the area of interest better. Sometimes several scans will be taken before Magnevist 2 mmol/l is injected and then further scans taken after the injection.
This medicine is for diagnostic use only.
Talk to your radiologist or MRI-centre staff before receiving Magnevist 2 mmol/l
Your doctor will need to take special care when giving you Magnevist 2 mmol/l if:
Before you receive Magnevist 2 mmol/l, you must tell the radiographer or MRI-centre staff if any of these apply to you.
Tell the radiologist or MRI-centre staff if you are taking, have recently taken or might take any other medicines.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask the MRI-centre staff for advice before receiving this medicine. A very small amount of Magnevist enters the breast milk, but this isn’t likely to cause any harm.
The volume of Magnevist 2 mmol/l injected into your joint may limit your movement.
Do not drive if your movement is affected.
This medicine contains 67.6 mg sodium (main component of cooking/table salt) per pre-filled syringe. This is equivalent to 3.38 % of the recommended maximum daily dietary intake of sodium for an adult.
You will be asked to sit or lie down and Magnevist 2 mmol/l will be injected into the joint which is being investigated. Scanning may start immediately after the Magnevist 2 mmol/l injection. The MRI staff will observe you for at least 30 minutes after the injection just in case you have any side effects.
Adults:
The dose of Magnevist 2 mmol/l varies depending on which joint is investigated. For most joints, 20 ml is used, but up to 50 ml may be used for the knee joint. The doctor will decide how much Magnevist 2 mmol/l is needed for your investigation.
Children:
Magnevist 2 mmol/l is not recommended for use in children.
Overdosing is unlikely. If this does occur no serious ill-effects are expected.
If you have any further questions on the use of this medicine, ask the MRI-centre staff.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects you may get after being given a contrast medium like Magnevist 2 mmol/l are usually mild to moderate.
If you notice:
Tell the radiologist or MRI staff immediately as these may be the first signs of allergic reaction or shock. Your investigation will need to be stopped and you may need further treatment.
Apart from the symptoms listed above, these are the possible side effects of Magnevist 2 mmol/l, starting with the more common ones:
Common may affect up to 1 in 10 people
sensations or reactions at the injection site (such as pain, joint pressure and temporary discomfort)
Uncommon may affect up to 1 in 100 people
feeling sick
dizziness
headache
Rare may affect up to 1 in 1,000 people
being sick
slowed heartbeat; lowered blood pressure; fainting
allergic-type skin reactions including itching, redness, wheals on the skin
Delayed reactions can occur (after hours or days), if you are concerned you should contact your doctor.
If you get any side effects, talk to your radiologist or MRI-centre staff. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.
Magnevist 2 mmol/l is a clear, colourless to pale yellow or brownish-yellow solution for injection.
Magnevist 2 mmol/l is available in 20 ml pre-filled syringes.
Marketing Authorisation Holder:
Manufacturer:
This leaflet was last revised in August 2020.
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000 (UK only)
Please be ready to give the following information:
Product name Reference number
MAGNEVIST® 2 mmol/l solution for injection 00010/0544
This is a service provided by the Royal National Institute of the Blind.
Magnevist® is a trademark of the Bayer Group.
V014_0
400 South Oak Way, Reading, Berkshire, RG2 6AD
+44 (0)118 206 3000